RYAH Medtech
Inc. Adds Over 100 Years of Medical Industry
Expertise to
Its Team
May
13,
2021;
(New
York, NY) — InvestorsHub
NewsWire –
RYAH
Group, Inc's (CSE:RYAH) ("RYAH"
or the "Company")
wholly
owned subsidiary, RYAH
Medtech
Inc. ("RYAH
Medtech"),
is pleased to announce that it has welcomed four
new
members to its business
development
team, namely Steven Schultz, Warren Thompson, Mitchell Zimmer
and Andrea Ferrari.
The newly added
experts bring extensive experience and expertise in the medical and
pharmaceutical industry:
Steven Schultz joins RYAH with $350
million
in sales
and 35 years of experience, including acting as
national account director at Johnson &
Johnson;
Warren Thompson, former
national
sales
director
at Ackermann U.S.A., brings 20 years of sales experience in
the
medical
device industry;
and
Mitch Zimmer,
who brings over 40
years of medical industry experience as an outstanding senior sales
expert, manager,
trainer
and mentor.
The team will be
focusing on expanding RYAH's presence in multiple verticals within
the North
America plant-based and nutraceutical
markets, including participation in clinical trials for the
Company's connected devices and custom software solutions in data
analytics for doctors, clinics, hospitals and
dispensaries.
Andrea
Ferrari,
former managing director of Aurora Italia,
joins the RYAH team to enhance the brand's presence in the European
market, bringing his unparalleled expertise into clinical
research implementation.
"We
are thrilled to announce these new appointments. This team has deep
acumen in the medical device and related industries, which will
allow us to capitalize on the changing regulatory environment and
to bring this experience to an even wider group of clinical,
medical and pharmaceutical clients worldwide,"
says
Gregory Wagner, CEO of RYAH and RYAH Medtech.
"We
are excited to welcome the new Business Development team, who all
have a proven record of facilitating long term business
relationships with both corporate customers and medical industry
luminaries,"
says
Sofiya Kleshchuk,
Head of Client Relations at RYAH Medtech.
About
RYAH Group,
Inc.
RYAH is a big data and
technology company focused on valuable predictive analysis in the
global medical intake industry. The company manages a complete
digital ecosystem leveraging both Internet of Things and Artificial
Intelligence to create a dynamic data service for the medical plant
industry. It is developing a suite of IoT devices, including a
dry-herb vaporizer device capable of storing all plant lab results,
measuring patient inhalation sessions in real-time and capturing
instant feedback for plant dose management. Its robust artificial
intelligence platform aggregates and correlates HIPAA-compliant
medical data, which is intended to help doctors and patients
personalize plant-based treatments to better predict treatment
outcomes. The data collection is also relevant for pharmacies,
clinics, growers, dispensaries and Licensed Processors (LPs) to
monitor and manage plant strain effects on patients. With a strong
IP portfolio, RYAH gathers deep and insightful data on the complete
medical plant lifecycle, from seed to consumption.
Forward-Looking Statements
Certain
statements contained in this press release constitute
"forward-looking information" as such term is defined in applicable
Canadian securities legislation. The words "may,"
"would,"
"could,"
"should,"
"potential,"
"will,"
"seek,"
"intend,"
"plan,"
"anticipate,"
"believe,"
"estimate,"
"expect" and similar expressions as they relate to the Company,
including,
the success
of the Company's clinical trials, the expansion of RYAH's
presence, and the
results users may receive from using RYAH,
are
intended to identify forward-looking information. All statements
other than statements of historical fact may be forward-looking
information. Such statements reflect the Company's current views
and intentions with respect to future events, and current
information available to the Company, and are subject to certain
risks, uncertainties and assumptions. Many factors could cause the
actual results, performance or achievements that may be expressed
or implied by such forward-looking information to vary from those
described herein should one or more of these risks or uncertainties
materialize. These factors include, without limitation: the general
business and economic conditions in the regions in which the
Company operates; the ability of the Company to execute on key
priorities, including the successful completion of acquisitions,
business retention, and strategic plans and to attract, develop and
retain key executives; difficulty integrating newly acquired
businesses; the ability to implement business strategies and pursue
business opportunities; disruptions in or attacks (including
cyber-attacks) on the Company's information technology, internet,
network access or other voice or data communications systems or
services; the evolution of various types of fraud or other criminal
behavior to which the Company is exposed; the failure of third
parties to comply with their obligations to the Company or its
affiliates; the impact of new and changes to, or application of,
current laws and regulations; a novel business model; granting of
permits and licenses in a highly regulated business; the overall
difficult litigation environment, including in the United States;
increased competition; changes in foreign currency rates; increased
funding costs and market volatility due to market illiquidity and
competition for funding; the availability of funds and resources to
pursue operations; critical accounting estimates and changes to
accounting standards, policies, and methods used by the Company;
the occurrence of natural and unnatural catastrophic events and
claims resulting from such events; and the risk associated with a
business in the cannabis industry. Should any factor affect the
Company in an unexpected manner, or should assumptions underlying
the forward-looking information prove incorrect, the actual results
or events may differ materially from the results or events
predicted. Any such forward-looking information is expressly
qualified in its entirety by this cautionary statement. Moreover,
the Company does not assume responsibility for the accuracy or
completeness of such forward-looking information. The
forward-looking information included in this press release is made
as of the date of this press release and the Company undertakes no
obligation to publicly update or revise any forward-looking
information, other than as required by applicable law
RYAH
Medtech Inc Contacts:
Sofiya
Kleshchuk
Client Relations
+1 917 210
0543
Invest@ryahgroup.com
Gregory
Wagner, CEO
917 210
0543
Info@ryah.com
Corporate
Communications:
InvestorBrandNetwork
(IBN)
Los
Angeles, California
www.InvestorBrandNetwork.com
310.299.1717
Office
Editor@InvestorBrandNetwork.com
RYAH (CSE:RYAH)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
RYAH (CSE:RYAH)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
